Active, not recruitingPhase 1NCT03613532

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Studying Acute myelomonocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jacqueline Garcia, MD
Principal Investigator
Jacqueline S. Garcia, MD
Dana-Farber Cancer Institute
Intervention
Venetoclax(drug)
Enrollment
102 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2027

Study locations (1)

Collaborators

National Institutes of Health (NIH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03613532 on ClinicalTrials.gov

Other trials for Acute myelomonocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute myelomonocytic leukemia →

← Back to all trials